http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
진행된 원발성 간암 환자에서 방사선 치료 및 온열 요법에 따른 간 기능의 변화
오영택 (Young Taek Oh),성진실 (Jinsil Seong),신현수 (Hyun Soo Shin),김귀언 (Gwi Eon Kim) 대한방사선종양학회 1993 Radiation Oncology Journal Vol.11 No.1
To analyze biochemical changes of liver function following combined radiotherapy and hyperthemia, we reviewed retrospectively 37 patients with hepatocellular carcinoma treated with radiotherapy and hyperthermia between July 1988 and December 1990 at Department of Radiation Oncology, Yonsei Universtiy College of Medicine. Mean age was 52.7 years and male to female ratio was 11:1. The patients were classified as follows; to A and B group by Child's classification, to M and L group by irradiated volume, and subclassified into BM, BL, AM and AL group according to the combination of child's classification and irradiated volume. Radiation dose to the primary tumor was 3060 cGy with daily 180 cGy, 5 fraction per week using 10 MV of 4 MV linear accelerator. Hyperthermia (Themotron RF-8) was performed more than 4 times in all patients. Biochemical parameters including albumin (Alb), total bilirubin (T. Bil), aspartate aminotransferase (AST or SGOT), alanine aminotransferase (ALT or SGPT), and alkaline phosphatase (ALP) were regularly followed form 1 week before the treatment to 3 months after the treatment. The results are summerized as follows;1) In all the patient, mean ALP level peaked at 1 month, decreased at 2 months, slightly increased at 3 months after the treatment. Mean SGOT and SGPT levels peaked at 1 month after the treatment. Mean T.Bil level increased continuously and highest at 3 months after the treatment. Mean Alv level did not show significant changes;2) Mean ALP level retured to normal level at 3 month after the treatment in A but increased in A but increased in B group and the differences were statistically significant (p
( Eun Young Woo ),( Gwi Taek Shin ),( Jin Young Lee ),( Chanmi Lim ),( Min Jung Choi ),( Suk Young Kim ) 대한주산의학회 2024 Perinatology Vol.35 No.1
Objective: To evaluate and assesse useful factors in predicting early preterm birth (PTB) and determined the increased risks of early PTB for the combinations of these factors compared to late PTB. Methods: The 77 singleton pregnancies with PTL were enrolled. They had undergone examinations including cervical length (CL) and fetal fibronectin (fFN), polymerase chain reaction for sexually transmitted disease, and cervical culture. We first evaluated the statistical significance of the primary predictors (known risk factors before pregnancy) and secondary predictors (fFN, CL, high-sensitivity C-reactive protein [hsCRP] and cervical bacterial analysis). Next, we analyzed the various combinations of meaningful factors. Results: CL <2.5 cm (P=0.007; odds ratio [OR], 3.598), hsCRP ≥0.9 mg/dL (P=0.011; OR, 3.79), and fFN ≥50 ng/mL (P=0.035; OR, 2.75) were more predictive of early PTB than late PTB. The highest OR was observed for the combination of all 3 factors (P=0.039; OR, 7.75). The fFN positivity and hsCRP ≥0.9 mg/dL was in OR 6.094 (P=0.013). The CL<2.5 cm and hsCRP ≥0.9 mg/dL was in OR 5.333 (P=0.009). Finally, the CL <2.5 cm and fFN positivity was in OR 3.946 (P=0.013). The interval between diagnosis and delivery in women with all 3 factors was 8 days shorter than that for women without these factors (P=0.04). Conclusion: Our study is the first to demonstrate the potential risks of PTB using the combination of commonly used in clinical factors, and revealed quantification by the ORs. We will be useful reference value for patients counselling for prediction of early PTB.
Song, Ji Hoon,Shin, Myoung-Sook,Hwang, Gwi Seo,Oh, Seong Taek,Hwang, Jung Jin,Kang, Ki Sung Elsevier 2018 Bioorganic & medicinal chemistry letters Vol.28 No.3
<P><B>Abstract</B></P> <P>Glutamate-induced excitotoxicity and oxidative stress is a major causative factor in neuronal cell death in acute brain injuries and chronic neurodegenerative diseases. The prevention of oxidative stress is a potential therapeutic strategy. Therefore, in the present study, we aimed to examine a potential therapeutic agent and its protective mechanism against glutamate-mediated cell death. We first found that chebulinic acid isolated from extracts of the fruit of <I>Terminalia chebula</I> prevented glutamate-induced HT22 cell death. Chebulinic acid significantly reduced intracellular reactive oxygen species (ROS) production and Ca<SUP>2+</SUP> influx induced by glutamate. We further demonstrated that chebulinic acid significantly decreased the phosphorylation of mitogen-activated protein kinases (MAPKs), including ERK1/2, JNK, and p38, as well as inhibiting pro-apoptotic Bax and increasing anti-apoptotic Bcl-2 protein expression. Moreover, we demonstrated that chebulinic acid significantly reduced the apoptosis induced by glutamate in HT22 cells. In conclusion, our results in this study suggest that chebulinic acid is a potent protectant against glutamate-induced neuronal cell death via inhibiting ROS production, Ca<SUP>2+</SUP> influx, and phosphorylation of MAPKs, as well as reducing the ratio of Bax to Bcl-2, which contribute to oxidative stress-mediated neuronal cell death.</P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
A case of Pseudo-Meigs syndrome associated with borderline mucinous ovarian tumor
( Da Hoe Jeong ),( Jin Young Lee ),( Gwi Taek Shin ),( Na Rae Kim ),( Jin Woo Shin ) 대한산부인과학회 2020 대한산부인과학회 학술대회 Vol.106 No.-
Pseudo-Meigs syndrome is a rare disease entity characterized by ovarian tumor coexisting with ascites and pleural effusion. These clinical features lead to gynecologists misdiagnosing it as ovarian carcinoma. In cases of Pseudo-Meigs syndrome, ascites and pleural effusion rapidly disappear after removal of the ovarian tumor, and the patient shows favorable prognosis. We report a case of Pseudo-Meigs syndrome with borderline mucinous ovarian tumor in a premenopausal woman. A 49-year-old premenopausal woman presented with dyspnea and a palpable abdominal mass. Abdominal and chest CT showed a 23 cm ovarian mass with ascites and right pleural effusion. Serum CA 125 and CA 19-9 levels were elevated. The patient underwent staging surgery and was diagnosed with borderline mucinous ovarian tumor. After surgery, the ascites and pleural effusion resolved. There was no metastasis or recurrence of the disease for two years after the surgery. To date, few reports have presented Pseudo-Meigs syndrome associated with borderline ovarian tumors. There was a case report about Pseudo-Meigs syndrome with borderline mucinous ovarian tumor in a postmenopausal woman in the English literature. In a study on premenopausal women, there was only one case of Pseudo-Meigs syndrome associated with borderline mucinous ovarian tumor and elevated serum CA 125 tumor marker, but her serum CA 19-9 levels were not checked. We report a case of Pseudo-Meigs syndrome with borderline mucinous ovarian tumor and elevated serum CA 125 and CA 19-9 levels in a premenopausal woman.
( Jin Young Lee ),( Mee Hyang Ko ),( Da Hoe Jeong ),( Hae Rin Jeon ),( Gwi Taek Shin ),( Suk Young Kim ) 대한산부인과학회 2020 대한산부인과학회 학술대회 Vol.106 No.-
The incidence of breast cancer during pregnancy is very rare, but if it occurs, it is mainly known as breast cancer, uterine cervix, lymphoma and melanoma. However, it is difficult to decide to undergo chemotherapy for treatment during pregnancy. Because such treatment can affect the growth and development in fetus such as growth retardation, oligohydramnios and fetal death. Thus, in this study, we reported how chemotherapy during pregnancy can affect the mother and fetus. We had experienced three cases that pregnant women in second trimester who were diagnosed breast cancer had undergone chemotherapy during pregnancy. Two of cases underwent surgical excision and lymph node dissection and then adjuvant chemotherapy. And one case undergone neoadjuvant chemotherapy. The delivery methods were two cesarean sections and one vaginal delivery. The one fetus had shown small for gestational age during gestation and was diagnosed microcephaly after birth, but is currently developing normally at 4 years of age. The other two fetuses were born without problems. One mother, who had just given birth, is undergoing chemotherapy for primary cancer, and two mothers have recurred and undergone chemotherapy. Base of our experiences with the three cases, it seems that chemotherapy during pregnancy does not significantly affect fetal outcomes. Therefore, pregnant women in second trimester who have been diagnosed with breast cancer should not hesitate to chemotherapy because of concerns about fetal development. However, it is important to help the patient understand the risk and benefits of such treatment through a detailed explanation and discussion and to have professional cooperation among the many related clinicians.